16.37 USD
+0.09 (+0.55%)
16.35 USD
-0.02 (-0.12%)
Taking everything into account, AUPH scores 6 out of 10 in our fundamental rating. AUPH was compared to 533 industry peers in the Biotechnology industry. AUPH is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AUPH is evaluated to be cheap and growing strongly. This does not happen too often! This makes AUPH very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
AUPH had positive earnings in the past year.
In the past year AUPH had a positive cash flow from operations.
In the past 5 years AUPH reported 4 times negative net income.
In the past 5 years AUPH reported 4 times negative operating cash flow.
1.2 Ratios
AUPH has a Return On Assets of 14.76%. This is amongst the best in the industry. AUPH outperforms 95.31% of its industry peers.
With an excellent Return On Equity value of 21.28%, AUPH belongs to the best of the industry, outperforming 96.44% of the companies in the same industry.
AUPH's Return On Invested Capital of 14.89% is amongst the best of the industry. AUPH outperforms 95.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROIC | 14.89% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AUPH has a better Profit Margin (29.28%) than 95.87% of its industry peers.
With an excellent Operating Margin value of 32.73%, AUPH belongs to the best of the industry, outperforming 96.81% of the companies in the same industry.
Looking at the Gross Margin, with a value of 88.93%, AUPH belongs to the top of the industry, outperforming 90.24% of the companies in the same industry.
In the last couple of years the Gross Margin of AUPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AUPH has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, AUPH has less shares outstanding
Compared to 5 years ago, AUPH has more shares outstanding
AUPH has a better debt/assets ratio than last year.
2.2 Solvency
AUPH has an Altman-Z score of 7.54. This indicates that AUPH is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AUPH (7.54) is better than 78.99% of its industry peers.
AUPH has a debt to FCF ratio of 0.60. This is a very positive value and a sign of high solvency as it would only need 0.60 years to pay back of all of its debts.
AUPH has a better Debt to FCF ratio (0.60) than 94.56% of its industry peers.
AUPH has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
AUPH's Debt to Equity ratio of 0.15 is on the low side compared to the rest of the industry. AUPH is outperformed by 64.73% of its industry peers.
Although AUPH does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Altman-Z | 7.54 |
ROIC/WACC1.95
WACC7.63%
2.3 Liquidity
A Current Ratio of 5.76 indicates that AUPH has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.76, AUPH is doing good in the industry, outperforming 60.60% of the companies in the same industry.
AUPH has a Quick Ratio of 5.17. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 5.17, AUPH perfoms like the industry average, outperforming 59.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 609.09% over the past year.
Looking at the last year, AUPH shows a very strong growth in Revenue. The Revenue has grown by 20.62%.
AUPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 279.17% yearly.
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
3.2 Future
AUPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.12% yearly.
The Revenue is expected to grow by 12.58% on average over the next years. This is quite good.
EPS Next Y634.77%
EPS Next 2Y193.81%
EPS Next 3Y118.33%
EPS Next 5Y68.12%
Revenue Next Year14.76%
Revenue Next 2Y14.54%
Revenue Next 3Y14.78%
Revenue Next 5Y12.58%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 29.23 indicates a quite expensive valuation of AUPH.
92.31% of the companies in the same industry are more expensive than AUPH, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.15. AUPH is around the same levels.
Based on the Price/Forward Earnings ratio of 21.07, the valuation of AUPH can be described as rather expensive.
93.06% of the companies in the same industry are more expensive than AUPH, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of AUPH to the average of the S&P500 Index (36.12), we can say AUPH is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.23 | ||
| Fwd PE | 21.07 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AUPH is valued cheaply inside the industry as 94.93% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 95.12% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.98 | ||
| EV/EBITDA | 14.89 |
4.3 Compensation for Growth
AUPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AUPH's earnings are expected to grow with 118.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y193.81%
EPS Next 3Y118.33%
5. Dividend
5.1 Amount
No dividends for AUPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.37
+0.09 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners45.31%
Inst Owner Change10.75%
Ins Owners1.92%
Ins Owner Change-0.39%
Market Cap2.15B
Revenue(TTM)265.81M
Net Income(TTM)77.84M
Analysts81.54
Price Target16.03 (-2.08%)
Short Float %6.83%
Short Ratio4.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.94%
Min EPS beat(2)6.95%
Max EPS beat(2)40.93%
EPS beat(4)4
Avg EPS beat(4)66.5%
Min EPS beat(4)6.95%
Max EPS beat(4)161.28%
EPS beat(8)7
Avg EPS beat(8)112.72%
EPS beat(12)11
Avg EPS beat(12)88.48%
EPS beat(16)14
Avg EPS beat(16)70.43%
Revenue beat(2)2
Avg Revenue beat(2)7.29%
Min Revenue beat(2)6.84%
Max Revenue beat(2)7.75%
Revenue beat(4)2
Avg Revenue beat(4)3.01%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)7.75%
Revenue beat(8)5
Avg Revenue beat(8)4.09%
Revenue beat(12)9
Avg Revenue beat(12)8.29%
Revenue beat(16)13
Avg Revenue beat(16)10.25%
PT rev (1m)34.15%
PT rev (3m)34.39%
EPS NQ rev (1m)30.44%
EPS NQ rev (3m)27.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.02%
Revenue NQ rev (1m)3.42%
Revenue NQ rev (3m)3.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.23 | ||
| Fwd PE | 21.07 | ||
| P/S | 8.11 | ||
| P/FCF | 17.98 | ||
| P/OCF | 17.94 | ||
| P/B | 5.89 | ||
| P/tB | 5.95 | ||
| EV/EBITDA | 14.89 |
EPS(TTM)0.56
EY3.42%
EPS(NY)0.78
Fwd EY4.75%
FCF(TTM)0.91
FCFY5.56%
OCF(TTM)0.91
OCFY5.57%
SpS2.02
BVpS2.78
TBVpS2.75
PEG (NY)0.05
PEG (5Y)N/A
Graham Number5.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.76% | ||
| ROE | 21.28% | ||
| ROCE | 19.28% | ||
| ROIC | 14.89% | ||
| ROICexc | 67.33% | ||
| ROICexgc | 70.07% | ||
| OM | 32.73% | ||
| PM (TTM) | 29.28% | ||
| GM | 88.93% | ||
| FCFM | 45.1% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score9
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.6 | ||
| Debt/EBITDA | 0.52 | ||
| Cap/Depr | 1.21% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.83% | ||
| Profit Quality | 154% | ||
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 7.54 |
F-Score9
WACC7.63%
ROIC/WACC1.95
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)609.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130%
EPS Next Y634.77%
EPS Next 2Y193.81%
EPS Next 3Y118.33%
EPS Next 5Y68.12%
Revenue 1Y (TTM)20.62%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%8.41%
Revenue Next Year14.76%
Revenue Next 2Y14.54%
Revenue Next 3Y14.78%
Revenue Next 5Y12.58%
EBIT growth 1Y448.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7028.23%
EBIT Next 3Y378.96%
EBIT Next 5YN/A
FCF growth 1Y414.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y421.82%
OCF growth 3YN/A
OCF growth 5YN/A
AURINIA PHARMACEUTICALS INC / AUPH FAQ
Can you provide the ChartMill fundamental rating for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to AUPH.
Can you provide the valuation status for AURINIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 7 / 10 to AURINIA PHARMACEUTICALS INC (AUPH). This can be considered as Undervalued.
What is the profitability of AUPH stock?
AURINIA PHARMACEUTICALS INC (AUPH) has a profitability rating of 5 / 10.
What are the PE and PB ratios of AURINIA PHARMACEUTICALS INC (AUPH) stock?
The Price/Earnings (PE) ratio for AURINIA PHARMACEUTICALS INC (AUPH) is 29.23 and the Price/Book (PB) ratio is 5.89.
What is the expected EPS growth for AURINIA PHARMACEUTICALS INC (AUPH) stock?
The Earnings per Share (EPS) of AURINIA PHARMACEUTICALS INC (AUPH) is expected to grow by 634.77% in the next year.